Position in KROS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$6,724,286
+$5,041,238 QoQ
Shares Held
628,438
+312.2% QoQ
Ownership
3.17%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#8
of 131 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in KROS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MACKENZIE FINANCIAL CORP holds $498,673,295 across 59 Biotechnology names. KROS ranks #17 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
135,783 | $84,666,131 | |
| 2 | INCY |
Incyte Corp
|
634,862 | $71,967,956 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
931,864 | $53,321,258 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
102,928 | $51,127,425 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
298,440 | $22,227,811 | |
| 6 | TBPH |
Theravance Biopharma, Inc.
|
985,848 | $16,759,416 | |
| 7 | RPRX |
Royalty Pharma plc
|
270,457 | $15,164,523 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
43,988 | $13,241,707 |
All Filings in KROS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,724,286 | 628,438 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $1,683,048 | 152,450 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $1,046,198 | 51,385 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $898,069 | 56,768 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $719,257 | 53,877 | Shares | Sole | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||